EMCDDA at 2019 European Conference on Addictive Behaviours and Dependencies

This week, EMCDDA staff members are revving up for ‘Lisbon Addictions 2019’, the third European Conference on Addictive Behaviours and Dependencies. Taking place from 23–25 October, ‘Lisbon Addictions’ is the largest European conference in the area of addictions, exploring the topics of illicit drugs, alcohol, tobacco, gambling and other addictive behaviours.

Over 1 300 participants from some 80 countries are registered for the event, which will showcase cutting-edge research to help characterise, understand and respond to addiction and addictive behaviours.

Over the three days, around 850 presentations will be given across 150 sessions, ranging from plenaries, ‘big debates’, workshops and guided e-poster tours. EMCDDA experts will be playing an active role, delivering close to 80 presentations and e-posters. These will cover topics ranging from drug-related deaths and the challenges of monitoring new drugs to drug checking technology and HCV testing and care. They will also be joining the Futures Zone, home to hands-on technology demonstrations and interactive workshops. Here the focus will be on forward-looking trends including digitalisation, innovative monitoring and new therapeutic horizons.

An exhibition stand at the event will showcase the latest EMCDDA products and services. The agency’s communication staff will be present on the stand to guide visitors and explore customer information needs.

The event is jointly organised by: the Portuguese General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD); the EMCDDA; the journal Addiction/Society for the Study of Addiction (Addiction/SSA); and the International Society of Addiction Journal Editors (ISAJE). SICAD Director-General João Goulão and EMCDDA Director Alexis Goosdeelwill deliver the welcoming remarks.

See list of EMCDDA presentations.

23 Oct Title Type of session
08:45 Welcoming remarks Plenary session
09:00 Introducing Lisbon Addictions 2019: The future is here, it's just not evenly distributed yet Plenary session
10:50 Analysis and monitoring of ongoing darknet drug purchases – FuturiZe discussion and demo Workshop
Focus on the EU borders – High-risk drug use and health threats in Eastern Europe Structured session
Innovative methods for exploring new drug-related trends Structured session
11:40 Drug and alcohol treatment: how much does it cost in Europe? Short communication session
11:45 ESCAPE (European Syringe Collection & Analysis Project Enterprise): a multi-city study of monitoring consumption trends of people who inject drugs Structured session
12:20 Prevalence and patterns of drug use indicator (‘GPS’) e-poster
European web survey on drugs: patterns of use e-poster
Measuring drug use to monitor trends in different populations - ISSDP session 1 e-poster
13:20 The challenges of monitoring new drugs Oral presentation session
The future of hepatitis C among people who inject drugs Structured session
Improving the validity of drug-related deaths data for policy making Structured session
Epidemiology of drug-related deaths in Europe, and focus in two countries on underestimation and possible corrections of the reported number of deaths  Structured session
13:30 A retrospective analysis of a turbulent decade for drug policy; 2009-2019 Structured session
15:00 Enhancing the role of drug treatment services for HCV elimination among people who inject drugs Structured session
The EMCDDA 'Harm reduction initiative' to promote access to hepatitis testing and care Structured session
15:10 Recognising that behaviour is often automatic, contingent on environmental cues and with limited self-regulation: the potentials of environmental prevention Oral presentation session
15:25 The Knowledge questionnaire for staff working with PWID: feedback from a pilot study among 150 health service workers Structured session
The treatment demand indicator in Europe: A common monitoring tool across 30 countries and its value for treatment systems planning Structured session
15:35 How HCV testing and care can be delivered through drug services: Evidence-base, case studies and 'real life' implementation experiences Structured session
16:50 Gender and drugs in Europe Structured session
New psychoactive substance use among marginalised and high risk populations in Europe Structured session
Migration, drug use and treatment Structured session
Prevalence and patterns of NPS use in general and school European populations Structured session
NPS use in self-selected respondents of the population (EU web-survey)  Structured session
17:00 Introduction and short presentation on harm reduction monitoring e-poster
17:15 Continuum of care for people who inject drugs Structured session
  Drug users in European prisons: a population with specific healthcare needs e-poster
  Recent changes in Europe’s cocaine market: results from an EMCDDA trendspotter study e-poster
24 Oct Title Type of session
10:50 A consensus approach to opioid substitution treatment outcomes and how they are monitored Oral presentation
Discussion and the future Structured session
Towards a consensus approach to opioid substitution treatment outcomes and how they are monitored Oral presentation
Drug-related interventions in European prisons Structured session
13:20 Drug-related deaths and mortality in Europe e-poster
Demand for drug treatment in Europe: the Treatment Demand indicator (TDI) e-poster
Injecting, risk and reducing harm Short communication session
Monitoring drug-related infectious diseases in Europe e-poster
Estimating the number of people who inject drugs (PWID) in Europe e-poster
13:30 Low THC cannabis products in the EU Structured session
15:00 Youth pathways Oral presentation
The cannabis policy kaleidoscope Structured session
Take-home naloxone — its role in preventing opioid-related deaths in Europe Structured session
Insight into the dynamics of substance use (research) in nightlife settings Structured session
15:10 Medical use of cannabis – a review of the regulatory frameworks and challenges Structured session
Epidemiology of drug-related deaths in Europe, new trends in opioid-related deaths Structured session
15:40 CBD and other low-THC cannabis products, the latest health fad or serious drug policy challenge Structured session
16:10 Reducing drug-related deaths: a systemic perspective and overview of current THN projects in Europe Structured session
16:50 Prison and drugs in Europe Structured session
European Drug Emergency Network Plus (Euro-DEN Plus) Structured session
Focus on the EU borders – Emerging drug trends in North Africa and Middle East Structured session
17:00 The European Drug Emergencies Network Plus (Euro-DEN Plus) project: what has it shown us over the last 5 years? Structured session
17:00 Cannabis use among people entering drug treatment. A growing phenomenon? Structured session
17:20 Captagon: knowns and unknows Structured session
17:35 Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe Oral presentation
18:30 Prevention science and measurement of demand reduction quality standards Oral presentation
Challenges for harm reduction II Oral presentation session
Opioids — current and emerging lessons Short communication session
  Recent changes in Europe’s cocaine market: results from an EMCDDA trendspotter study e-poster
  Drug users in European prisons: a population with specific healthcare needs e-poster
25 Oct Title Type of session
09:00 Illicit drug markets: strategic analysis for a safer Europe Structured session
09:10 A framework for understanding the EU illicit drug market  Structured session
09:25 Ramifications of illicit drug markets: pilot data on drug-related homicide  Structured session
09:55 The European markets for cannabis, heroin and cocaine  Structured session
10:10 The European markets for synthetic stimulants and new psychoactive substances Oral presentation session
10:45 Approaches to support the development of an evaluative culture to promote better drug policy for the future Structured session
Epidemiology of infectious diseases Oral presentation session
11:25 The role of evaluation in the development of the EU approach on drugs Structured session
11:40 Developing a flexible support package for EU Member States: EMCDDA’s ‘realistic’ policy evaluation approach Structured session
  Drug users in European prisons: a population with specific healthcare needs e-poster
  Recent changes in Europe’s cocaine market: results from an EMCDDA trendspotter study e-poster

Spotlight

Top